NanoBone®
Rapid Osteogenesis

FOR IMMEDIATE RELEASE

Contact:
Paul Byerley
Chief Executive Officer
+1 320.259.4321
pbyerley@artossinc.com

Artoss Announces NanoBone® QD Bone Graft

NanoBone QD allows for expanded orthopaedic clinical use

St. Cloud, MN, October 23, 2017/ -- Artoss, Inc. (St. Cloud, MN), a medical device company that is pioneering the use of advanced bone graft substitutes to treat multiple orthopaedic indications, announced the launch of NanoBone QD Bone Graft.

Paul Byerley, Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone® in orthopaedic surgery, said, "To extend the usability of NanoBone, we put the perfect handling of NanoBone SBX Putty in an applicator designed for QD – quick delivery. This easy-to-use device facilitates rapid implantation of our advanced bone graft in a controlled and precise manner. Artoss developed NanoBone QD to provide these benefits in a cost-effective delivery system."

Walter Gerike, Managing Director of Artoss GmbH said, "Nanotechnology is the key technology for the 21st century and Artoss is harnessing this potential for orthopaedic surgery. With the launch of NanoBone SBX Putty in 2016, we created a product that combines Applied NanoBiology™ for bone repair with perfect handling for the surgeon. NanoBone QD takes the product one step further by making it easier for the surgeon to implant." NanoBone synthetic bone graft products have been used in Europe and the US for more than ten years in approaching 100,000 clinical cases across all indications and has been available in the United States since 2015.

Artoss, Inc. is launching NanoBone QD at the North American Spine Society Meeting this week. Visit them at Booth 1562 to learn more.

NanoBone has consistent and cost-effective outcomes in bone grafting in multiple orthopaedic indications. NanoBone achieves these outcomes with no preparation required, excellent handling for surgeons, creation of an osteogenic matrix within 14 days, and clinical and radiographic healing in as little as 8 weeks. The dramatic growth in NanoBone procedures further secures its growing market position as a leader in the bone repair space. There is growing acceptance by surgeons that not all bone graft substitutes are the same, given the rapid osteogenic matrix formation of NanoBone within 14 days.

###

About NanoBone

NanoBone was first cleared by the Food and Drug Administration (FDA) in 2015 after having been successfully used in Europe for ten years. Clinical publications have identified bone graft substitutes as an increasingly important component of many orthopaedic procedures. Consistent healing in orthopaedic procedures is a significant unmet clinical need and one where NanoBone may provide an effective option.

NanoBone is a commercially available product in the U.S. intended to fill bony voids or gaps of the skeletal system (i.e., extremities, posterolateral spine and pelvis). These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NanoBone® SBX Putty resorbs and is replaced with bone during the healing process.

###

About Artoss, Inc.

Artoss, Inc. (St. Cloud, MN) is a medical device company that is a leading distributor of bioidentical bone graft substitutes to treat multiple orthopaedic indications and is dedicated to the development of tools and products for effectively treating a variety of orthopaedic conditions requiring surgical intervention. The company markets, NanoBone Bone Graft Substitute, which is gives clinical outcomes comparable to autograft with less postoperative pain and complications. Artoss, Inc. has an experienced management team with extensive experience in orthopaedic medical devices.